Given the overall safety and efficacy data investigated in this systematic literature review and meta-analysis, the newer IL12/23- and IL17-targeting biologics seem preferable to the older TNF inhibitors for a majority of pediatric patients with moderate-to-severe psoriasis. The gene discussed is IL17A; the disease is psoriasis.